Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Phase 1 Study of PYX-201 in Solid Tumors Recruiting

2023-509687-14-00 Advanced solid tumors 1 2024-08-29
DICIT: Efficacy of diclofenac added to an approved, ongoing PD-1 inhibitor therapy that achieved stable disease as best response in metastat… Recruiting

2023-504191-26-00 Metastatic Melanoma 10 2024-08-23
First-in-human study of 225Ac-PSMA-Trillium (BAY 3563254) in participants with advanced metastatic castration-resistant prostate cancer (mCR… Recruiting

2023-507486-26-00 Advanced metastatic castration-resistant prostate cance 1 2024-08-20
An Open-Label, Multicenter, Multi-Arm Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1805 in Adults with Advanced Solid Tum… Recruiting

2022-502757-34-00 Advanced solid tumors 1 2024-08-20
EFFIPEC Recruiting

2024-516224-34-00 Colorectal cancer 5 2024-08-16
ADP-TILIL7 Recruiting

2023-509665-20-00 Locally advanced or metastatic melanoma 1 2024-08-15
Dendritic cell therapy combined with surgery in mesothelioma (ENSURE) Recruiting

2024-514054-70-00 Adult patients diagnosed with resectable epithelioid MP 1 2024-08-12
Exploratory clinical trial to assess safety, tolerability efficacy and pharmacokinetics of CEB-01 PLGA membrane in participants with pancrea… Recruiting

2024-512742-42-00 Pancreatic carcinoma 4 2024-08-09
The RED FLASH study Recruiting

2023-507847-13-00 Breast cancer 5 2024-08-09
First-in-Human Study of OKI-219 Alone and in Combination with Other Therapies in Patients with Solid Tumors / Breast Cancer Recruiting

2023-508435-31-00 Advanced Solid Tumors, Advanced Breast Cancer 1 2024-08-09
The CLEAN-DUCT / TRITICC-3 trial - Phase IIa, prospective, single arm, open label, non-randomized, multi-center pilot study of durvalumab (M… Recruiting

2023-509165-21-00 Extrahepatic cholangiocarcinoma (eCCA) 4 2024-08-08
A Trial to Learn if Linvoseltamab is Safe and Works in Adults with Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) Recruiting

2023-507809-34-00 Relapsed or Refractory Systemic Light Chain Amyloidosis 9 2024-08-07
First-in human, dose escalation and cohort expansion study for the evaluation of LB-208 (HTR1B antagonist) in adult patients with relapsed o… Recruiting

2023-509532-25-00 Solid tumor 1 2024-08-07
A Phase 1, Open-Label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preli… Recruiting

2023-506199-28-00 Dose escalation: Advanced Solid Tumors Dose Expansion: 1 2024-08-05
A clinical study of MK-2870 alone or with other treatments to treat gastrointestinal cancers (MK-9999-02A) Recruiting

2023-508703-21-00 Colorectal cancer (CRC), pancreatic ductal adenocarcino 9 2024-08-01
A study of the safety and efficacy of MB-dNPM-1-TCR.1 in patients with relapsed or refractory AML. Recruiting

2023-505806-41-00 Acute myeloid leukemia 7 2024-08-01
PHASE Ib STUDY WITH THE COMBINATION OF LB–100 (PP2A INHIBITOR) AND ATEZOLIZUMAB (PD–L1 INHIBI-TOR) IN METASTATIC COLORECTAL CANCER PATIENTS … Recruiting

2023-505534-98-00 Microsatellite stable colorectal cancer patients 1 2024-08-01
Study evaluating the Safety and Efficacy of Etentamig (ABBV-383) in Subjects with Light Chain Amyloidosis Recruiting

2023-503429-20-00 Light Chain Amyloidosis 8 2024-07-31
SALVOVAR trial: A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVa… Recruiting

2023-508260-30-01 Patients with poor prognostic OVARian cancers based on 5 2024-07-30
A multicenter, open label, two cohort, single arm, phase II study to evaluate the efficacy and safety of the anti-TROP2 antibody-drug conjug… Recruiting

2023-504898-20-00 Thyroid neoplasms: ● Cohort 1: Advanced radioactive-iod 4 2024-07-30
Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizu… Recruiting

2024-515788-73-00 MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCE 4 2024-07-30
A Phase 1 Study of JNJ-88549968, a T-cell Redirecting Antibody, for CALR-mutated Myeloproliferative Neoplasms Recruiting

2023-505584-36-00 CALR-mutated Myeloproliferative Neoplasms 1 2024-07-30
A PHASE I STUDY OF XXX AS SINGLE AGENT OR IN COMBINATION WITH ANTI-PD-1 ANTIBODY IN SOLID CANCERS AND A RANDOMIZED COHORT EXPLORING THE COMB… Recruiting

2024-512175-12-00 Low tumour volume (LTV) advanced, metastatic, or recurr 1 2024-07-29
Treatment of cancer with Immune Checkpoint Inhibition therapy boosted by High Intensity Focused Ultrasound Histotripsy (the iFOCUS study) Recruiting

2023-509210-10-00 Metastatic or unresectable solid malignancies. Standard 3 2024-07-26